1887

Abstract

Purpose. We assessed the synergistic potential of fosfomycin and parenteral antibiotics among carbapenem-resistant Pseudomonas aeruginosa (CRP).

Methodology. Minimum inhibitory concentrations (MICs) were determined by broth microdilution for all antibiotics except fosfomycin, for which the gradient diffusion strip (GDS) method was used. The GDS cross method was performed to assess interactions between fosfomycin and: aztreonam, cefepime, ceftazidime, ceftazidime/avibactam, ceftolozane/tazobactam, meropenem, piperacillin/tazobactam and tobramycin. Only organisms that were nonsusceptible to the second drug were assessed.

Results. Among 153 clinical isolates, the fosfomycin MIC50/90 was 48/≥1024 mg l . Synergy was detected in 131/604 (21.7 %) fosfomycin–antibiotic combinations among 76 (49.7 %) isolates. Ceftazidime (42/81, 51.9%) and ceftolozane/tazobactam (7/14, 50.0%) displayed synergy most frequently. Meropenem susceptibility was restored in 21 (13.7 %) isolates. Antagonism was not observed.

Conclusion. Fosfomycin synergy was commonly observed in vitro among CRP. These data may guide the selection of combination antibiotic therapy. The susceptibility to other antibiotics was restored in combination with fosfomycin, warranting further in vivo evaluation.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000984
2019-05-03
2019-10-19
Loading full text...

Full text loading...

References

  1. Buehrle DJ, Shields RK, Clarke LG, Potoski BA, Clancy CJ et al. Carbapenem-resistant Pseudomonas aeruginosa bacteremia: risk factors for mortality and microbiologic treatment failure. Antimicrob Agents Chemother 2017;61:e01243–16 [CrossRef]
    [Google Scholar]
  2. Jeong SJ, Yoon SS, Bae IK, Jeong SH, Kim JM et al. Risk factors for mortality in patients with bloodstream infections caused by carbapenem-resistant Pseudomonas aeruginosa: clinical impact of bacterial virulence and strains on outcome. Diagn Microbiol Infect Dis 2014;80:130–135 [CrossRef]
    [Google Scholar]
  3. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 2018;18:318–327 [CrossRef]
    [Google Scholar]
  4. Bassetti M, Carnelutti A, Peghin M. Patient specific risk stratification for antimicrobial resistance and possible treatment strategies in Gram-negative bacterial infections. Expert Rev Anti Infect Ther 2017;15:55–65 [CrossRef]
    [Google Scholar]
  5. Avery LM, Nicolau DP. Investigational drugs for the treatment of infections caused by multidrug-resistant Gram-negative bacteria. Expert Opin Investig Drugs 2018;27:325–338 [CrossRef]
    [Google Scholar]
  6. Årdal C, Outterson K, Hoffman SJ, Ghafur A, Sharland M et al. International cooperation to improve access to and sustain effectiveness of antimicrobials. Lancet 2016;387:296–307 [CrossRef]
    [Google Scholar]
  7. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M et al. Surviving sepsis campaign. Crit Care Med 2017;45:486–552 [CrossRef]
    [Google Scholar]
  8. Ferrer R, Martin-Loeches I, Phillips G, Osborn TM, Townsend S et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour. Crit Care Med 2014;42:1749–1755 [CrossRef]
    [Google Scholar]
  9. Retamar P, Portillo MM, López-Prieto MD, Rodríguez-López F, de Cueto M et al. Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: a propensity score-based analysis. Antimicrob Agents Chemother 2012;56:472–478 [CrossRef]
    [Google Scholar]
  10. Marquet K, Liesenborgs A, Bergs J, Vleugels A, Claes N. Incidence and outcome of inappropriate in-hospital empiric antibiotics for severe infection: a systematic review and meta-analysis. Crit Care 2015;19:63 [CrossRef]
    [Google Scholar]
  11. Maraolo AE, Cascella M, Corcione S, Cuomo A, Nappa S et al. Management of multidrug-resistant Pseudomonas aeruginosa in the intensive care unit: state of the art. Expert Rev Anti Infect Ther 2017;15:861–871 [CrossRef]
    [Google Scholar]
  12. Khawcharoenporn T, Chuncharunee A, Maluangnon C, Taweesakulvashra T, Tiamsak P. Active monotherapy and combination therapy for extensively drug-resistant Pseudomonas aeruginosa pneumonia. Int J Antimicrob Agents 2018;52:828–834 [CrossRef]
    [Google Scholar]
  13. Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. Fosfomycin. Clin Microbiol Rev 2016;29:321–347 [CrossRef]
    [Google Scholar]
  14. Patient Safety Atlas - PSA Centers for disease control and prevention. https://gis.cdc.gov/grasp/PSA/MapView.html June 19, 2018
  15. Clinical and Laboratory Standards Institute (CLSI) Performance Standards for Antimicrobial Susceptibility Testing, 28th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2018
  16. Pankey GA, Ashcraft DS, Dornelles A. Comparison of 3 Etest® methods and time-kill assay for determination of antimicrobial synergy against carbapenemase-producing Klebsiella species. Diagn Microbiol Infect Dis 2013;77:220–226 [CrossRef]
    [Google Scholar]
  17. Hall MJ, Middleton RF, Westmacott D. The fractional inhibitory concentration (FIC) index as a measure of synergy. J Antimicrob Chemother 1983;11:427–433 [CrossRef]
    [Google Scholar]
  18. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003;52:1 [CrossRef]
    [Google Scholar]
  19. Drusano GL, Neely MN, Yamada WM, Duncanson B, Brown D et al. The Combination of fosfomycin plus meropenem is synergistic for Pseudomonas aeruginosa PAO1 in a hollow-fiber infection model. Antimicrob Agents Chemother 2018;62:e01682–18 [CrossRef]
    [Google Scholar]
  20. Bilal H, Peleg AY, McIntosh MP, Styles IK, Hirsch EB et al. Elucidation of the pharmacokinetic/pharmacodynamic determinants of fosfomycin activity against Pseudomonas aeruginosa using a dynamic in vitro model. J Antimicrob Chemother 2018;73:1570–1578 [CrossRef]
    [Google Scholar]
  21. Lepak AJ, Zhao M, VanScoy B, Taylor DS, Ellis-Grosse E et al. In Vivo pharmacokinetics and pharmacodynamics of ZTI-01 (fosfomycin for injection) in the neutropenic murine thigh infection model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2017;61:e00476–17 [CrossRef]
    [Google Scholar]
  22. Monogue ML, Nicolau DP. Antibacterial activity of ceftolozane/tazobactam alone and in combination with other antimicrobial agents against MDR Pseudomonas aeruginosa. J Antimicrob Chemother 2018;73:942–952 [CrossRef]
    [Google Scholar]
  23. Avery LM, Nicolau DP. Feasibility of routine synergy testing using antibiotic gradient diffusion strips in the clinical laboratory. J Antimicrob Chemother 2018;73:2264–2265 [CrossRef]
    [Google Scholar]
  24. Samonis G, Maraki S, Karageorgopoulos DE, Vouloumanou EK, Falagas ME. Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates. Eur J Clin Microbiol Infect Dis 2012;31:695–701 [CrossRef]
    [Google Scholar]
  25. Okazaki M, Suzuki K, Asano N, Araki K, Shukuya N et al. Effectiveness of fosfomycin combined with other antimicrobial agents against multidrug-resistant Pseudomonas aeruginosa isolates using the efficacy time index assay. J Infect Chemother 2002;8:37–42 [CrossRef]
    [Google Scholar]
  26. Dijkmans AC, Zacarías NVO, Burggraaf J, Mouton JW, Wilms E et al. Fosfomycin: pharmacological, clinical and future perspectives. Antibiotics 2017;6:24 [CrossRef]
    [Google Scholar]
  27. Hamou-Segarra M, Zamorano L, Vadlamani G, Chu M, Sanchez-Diener I et al. Synergistic activity of fosfomycin, β-lactams and peptidoglycan recycling inhibition against Pseudomonas aeruginosa. J Antimicrob Chemother 2017;72:448–454 [CrossRef]
    [Google Scholar]
  28. Díez-Aguilar M, Martínez-García L, Cantón R, Morosini MI. Is a new standard needed for diffusion methods for In vitro susceptibility testing of fosfomycin against Pseudomonas aeruginosa?. Antimicrob Agents Chemother 2016;60:1158–1161 [CrossRef]
    [Google Scholar]
  29. EUCAST EUCAST warnings. http://www.eucast.org/ast_of_bacteria/warnings/ May 1, 2018
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000984
Loading
/content/journal/jmm/10.1099/jmm.0.000984
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error